Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
28 Agosto 2024 - 9:00AM
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the
“Company”), today announced it will be participating in the H.C.
Wainwright 26th Annual Global Investment Conference, being held
September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of
Conduit, will give a virtual presentation available on-demand
starting on September 9th at 7:00 am ET/12:00 pm BST. Dr. Tapolczay
will also be available for in-person, one-on-one investor meetings
throughout the conference being held at Lotte New York Palace
Hotel, 455 Madison Avenue, New York City.
To view Dr. Tapolczay’s presentation, please use the following
link to register via H.C. Wainwright’s website
(www.hcwevents.com/annualconference). A webcast of the presentation
will also be available on the Company Events section of the
Company’s website at (www.conduitpharma.com).
About Conduit Pharmaceuticals
Conduit is a multi-asset, clinical stage, disease-agnostic life
science company delivering an efficient model for compound
development. Conduit both acquires and funds the development of
Phase 2-ready assets and then seeks an exit through third-party
license deals following successful clinical trials. Led by a highly
experienced team of pharmaceutical executives including Dr. David
Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a
departure from the traditional pharma/biotech business model of
taking assets through regulatory approval.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws. All statements
other than statements of historical facts contained in this press
release, including statements regarding Conduit's future results of
operations and financial position, Conduit's business strategy,
prospective product candidates, product approvals, research and
development costs, timing and likelihood of success, plans and
objectives of management for future operations, future results of
current and anticipated studies and business endeavors with third
parties, and future results of current and anticipated product
candidates, are forward-looking statements. These forward-looking
statements generally are identified by the words "believe,"
"project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result,"
and similar expressions. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions,
including, but not limited to; the inability to maintain the
listing of Conduit's securities on Nasdaq; the ability to recognize
the anticipated benefits of the business combination completed in
September 2023, which may be affected by, among other things,
competition; the ability of the combined company to grow and manage
growth economically and hire and retain key employees; the risks
that Conduit's product candidates in development fail clinical
trials or are not approved by the U.S. Food and Drug Administration
or other applicable authorities on a timely basis or at all;
changes in applicable laws or regulations; the possibility that
Conduit may be adversely affected by other economic, business,
and/or competitive factors; and other risks as identified in
filings made by Conduit with the U.S. Securities and Exchange
Commission. Moreover, Conduit operates in a very competitive and
rapidly changing environment. Because forward-looking statements
are inherently subject to risks and uncertainties, some of which
cannot be predicted or quantified and some of which are beyond
Conduit's control, you should not rely on these forward-looking
statements as predictions of future events. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and except as required by law, Conduit assumes no obligation and
does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. Conduit gives no assurance that it will achieve its
expectations.
InvestorsBill Begien Conduit Pharmaceuticals
Inc. bb@conduitpharma.com
Conduit Pharmaceuticals (NASDAQ:CDT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Conduit Pharmaceuticals (NASDAQ:CDT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024